JARDIANCE® provides triple protection in your patients with CRM conditions:
reduced risk of CV death
or kidney disease progression*1,2
reduced risk of CV death
or hospitalisation for heart failure†3,4
reduced risk of CV death‡5
Prof. Christoph Wanner - For you as a nephrologist in your daily practice, what is the most impactful outcome that was shown in the EMPA-KIDNEY¹ trial?
14/03/2024 | Author: Boehringer Ingelheim
Document ID: PC-MY-103558